We offer experience combined with the most flexible approach. We operate multiple platforms, have run many challenging sample types, developed new methodologies and run our own scientific experiments. The quality of our data is validated and is used as a standard for the FDA. Our combination of experience, quality and flexibility ensures that we best meet your needs.

Ocimum Biosolutions, a leading integrated life sciences solutions company, has been listed in the third annual Inc. 5000, an exclusive ranking of the America’s fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy—America’s independent-minded entrepreneurs.

Ocimum Biosolutions Inc. announced today that it has agreed to buy Gene Logic’s Genomics Business for $ 10 million in cash. The purchase includes Gene Logic’s Knowledge Products business which is anchored by the world’s largest databases of human biology (BioExpress®) and response to treatment (ToxExpress®) integrated with the Genesis™ software system and expanded through web-enabled products like Ascenta™, Sciantis™ and ToxShield™. As part of the transaction, Ocimum has also acquired Gene Logic’s comprehensive genomic and genetic services business which provides customers with access to a biorepository of over 80,000 unique samples, targeted sample accrual using its significant clinical network, data generation on multiple platforms including Affymetrix, Agilent, ABI and others, and biostatistical and other data analysis services.

Ocimum Biosolutions Inc. announced today that it has agreed to buy Gene Logic’s Genomics Business for $ 10 million in cash. The purchase includes Gene Logic’s Knowledge Products business which is anchored by the world’s largest databases of human biology (BioExpress®) and response to treatment (ToxExpress®) integrated with the Genesis™ software system and expanded through web-enabled products like Ascenta™, Sciantis™ and ToxShield™. As part of the transaction, Ocimum has also acquired Gene Logic’s comprehensive genomic and genetic services business which provides customers with access to a biorepository of over 80,000 unique samples, targeted sample accrual using its significant clinical network, data generation on multiple platforms including Affymetrix, Agilent, ABI and others, and biostatistical and other data analysis services. Ocimum will continue to operate the business out of the current state-of-the-art laboratory facility in Gaithersburg, Maryland.